000			02091nam a2200469 i 4500
001			ocn946944315
003			OCoLC
005			20160809093803.0
007			he bmb024bbca
008			160419s2015 dcua bb f000 0 eng c
040			_aGPO _beng _erda _cGPO
042			_apcc
043			_an-us---
050	1	4	_aKF31 _b.F5 2015
074			_a1038-B (MF)
086	0		_aY 4.F 49:S.PRT.114-20/
099			_aY 4.F 49:S.PRT.114-20/
245	0	4	_aThe price of Sovaldi and its impact on the U.S. health care system / _cprepared by the staffs of ranking member Ron Wyden and committee member Charles E. Grassley, Committee on Finance, United States Senate.
264		1	_aWashington : _bU.S. Government Publishing Office, _c2015.
264		2	_aWashington, DC : _bFor sale by the Superintendent of Documents, U.S. Government Publishing Office
300			_a2 volumes (viii, 1980 pages) : _billustrations ; _c24 cm.
336			_btxt
337			_bh _2rdamedia
338			_bhe _2rdacarrier
490	1		_aS. prt. ; _v114-20
500			_aAt head of title: 114th Congress, 1st session. Committee print.
500			_aShipping list no.: 2016-0082-M.
500			_a"December 2015."
500			_aCRDP Project record.
504			_aIncludes bibliographical references.
533			_aMicrofiche. _b[Washington, D.C.] : _cU.S. Government Printing Office, _d[2016] _e34 microfiches : negative.
650		0	_aSofosbuvir _xPrices _zUnited States.
650		0	_aHepatitis C _xChemotherapy _zUnited States _xCosts.
650		0	_aSulfonamides _xPrices _zUnited States.
650		0	_aAntiviral agents _xPrices _zUnited States.
610	2	0	_aGilead Sciences (Firm)
655		7	_aLegislative materials. _2lcgft
710	1		_aUnited States. _bCongress. _bSenate. _bCommittee on Finance, _eissuing body.
776	0	8	_iPrint version: _tPrice of Sovaldi and its impact on the U.S. health care system _w(OCoLC)932019028
776	0	8	_iOnline version: _tPrice of Sovaldi and its impact on the U.S. health care system _w(OCoLC)932136752
830		0	_aS. prt. ; _v114-20.
999			_c253290 _d253290